CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2024. Highlights: Recognized record total revenue of $15.1 million in the second quarter of 2024. Delivered gross margin of 60.1% in the second quarter of 2024, compared to a gross margin of 58.7% in the second quarter of 2023. AVISE® CTD trailing twelve-month average selling price (ASP) of $401, a 25.3% increase ove ...